ABIONYX Pharma SA

As of December 31, 2025, ABIONYX Pharma SA carries a market capitalization of 135.70M, placing it among publicly traded companies globally. Its enterprise value stands at 135.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ABIONYX Pharma SA's next confirmed earnings release is scheduled for March 16, 2027.

As of December 31, 2025, ABIONYX Pharma SA has 35.84M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, ABIONYX Pharma SA maintains a current ratio of 1.06, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 21, 2026, ABIONYX Pharma SA's stock has declined approximately 47.93% over the past 52 weeks. The 50-day moving average sits at 1.81, while the 200-day moving average is 2.84.

As of December 31, 2025, ABIONYX Pharma SA holds 3.52M in cash and equivalents against 3.81M in total debt, resulting in a net debt position of -1.10M. Total book value stands at 4.51M, with working capital of 304,000.00 providing operational flexibility.

ABIONYX Pharma SA's most recent stock split took place on May 29, 2026 with a 65:66 split ratio.